ClinicalTrials.gg
CompletedNCT01908426CELESTIALUpdated May 6, 2021Results posted

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

A Phase 3 interventional study of Cabozantinib tablets and Placebo tablets in Hepatocellular Carcinoma, sponsored by Exelixis. Completed at 104 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-06.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
707
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing cabozantinib in Carcinoma, Hepatocellular — 7 open to participants now, 11 under way, 2 of them phase 3. cabozantinib · Carcinoma, Hepatocellular.

Enrollment
5th of 27
707 · median 35
Started
2013
the only one that year
Phase 3
3 of 27
1 open now
Registered
3rd of 27
by date
Lead sponsor
5 of 27
Exelixis

Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 3rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 27 studies testing cabozantinib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cabozantinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • cabozantinib
  • XL184
  • liver cancer
  • hepatocellular carcinoma
  • tyrosine kinase inhibitor
  • MET kinase
  • vascular endothelial growth factor receptor 2 (VEGFR2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Select Inclusion Criteria:

  1. Histological or cytological diagnosis of HCC.
  2. The subject has disease that is not amenable to a curative treatment approach.
  3. Received prior sorafenib.
  4. Progression following at least 1 prior systemic treatment for HCC.
  5. Recovery to from toxicities related to any prior treatments.
  6. performance status of 0 or 1.
  7. Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within 7 days before randomization.
  8. Score of A.
  9. Antiviral therapy per local standard of care if active (HBV) infection.
  10. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of during the course of the study and for 4 months after the last dose of study treatment.
  11. Female subjects of must not be pregnant at screening.

Select Exclusion Criteria:

  1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
  2. Receipt of more than 2 prior systemic therapies for advanced HCC.
  3. Any type of anticancer agent (including ) within 2 weeks before randomization.
  4. Radiation therapy within 4 weeks (2 weeks for radiation for bone ) or radionuclide treatment within 6 weeks of randomization.
  5. Prior cabozantinib treatment.
  6. Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.
  7. Concomitant anticoagulation, at therapeutic doses, with anticoagulants.
  8. Serious illness other than cancer that would preclude safe participation in the study.
  9. Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding.
  10. Moderate or severe ascites.
  11. Pregnant or lactating females.
  12. Diagnosis of another within 2 years before randomization, except for superficial skin cancers, or localized, low-grade tumors.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
707 participants (actual)

Study arms

  • Experimental
    Cabozantinib (XL184)

    Cabozantinib (XL184) 60 mg tablet once daily

    Drug: Cabozantinib tablets

  • Placebo comparator
    Placebo

    Oral cabozantinib-matched placebo tablet once daily

    Drug: Placebo tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.

    Time frame: Up to 45 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.

    Time frame: Up to 45 months

  2. Objective Response Rate (ORR)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment (up to 45 months)

07

Results

Posted Mar 1, 2019

Participant flow

First patient enrolled: 26 September 2013, Data cut-off date: 01 June 2017

Participant flow — Overall Study
MilestoneCabozantinib (XL184)Placebo
Started470237
Completed7326
Not completed397211
Withdrew: Adverse event9811
Withdrew: Clinical deterioration7238
Withdrew: Lack of efficacy30
Withdrew: Lost to follow-up01
Withdrew: Physician decision33
Withdrew: Withdrawal by subject116
Withdrew: Progressive disease206152
Withdrew: Protocol violation10
Withdrew: No study treatment given30

Outcome measures

PrimaryOverall Survival (OS)

The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.

Time frame:
Up to 45 months
Reported as:
Median · months
Overall Survival (OS)
monthsCabozantinib (XL184)Placebo
Overall Survival (OS)10.2 (9.1 to 12.0)8.0 (6.8 to 9.4)
Statistical analysis
  • Cabozantinib (XL184) vs Placebo · Log Rank · p = 0.0049 · Hazard ratio (hr): 0.76 · 95% CI 0.63 to 0.92The Log-Rank Test was stratified by etiology of disease, geo. region, presence of extrahepatic spread of disease and/or macrovascular invasion.
SecondaryProgression-Free Survival (PFS)

Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.

Time frame:
Up to 45 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCabozantinib (XL184)Placebo
Progression-Free Survival (PFS)5.2 (4.0 to 5.5)1.9 (1.9 to 1.9)
Statistical analysis
  • Cabozantinib (XL184) vs Placebo · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.44 · 95% CI 0.36 to 0.52The Log Rank Test was stratified by etiology of disease, geographic region, presence of extrahepatic spread of disease and/or macrovascular invasion.
SecondaryObjective Response Rate (ORR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment (up to 45 months)
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsCabozantinib (XL184)Placebo
Objective Response Rate (ORR)181
Statistical analysis
  • Cabozantinib (XL184) vs Placebo · Cochran-Mantel-Haenszel · p = 0.0086

Adverse events

Collected over Up to 61 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib (XL184)314/467 (67.2%)232/467 (49.7%)445/467 (95.3%)
Placebo167/237 (70.5%)87/237 (36.7%)173/237 (73%)
Most frequent serious events
Showing 10 of 240
Most frequent serious events
EventCabozantinib (XL184)Placebo
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)39/46722/237
Abdominal PainGastrointestinal disorders6/4679/237
General physical health deteriorationGeneral disorders17/4678/237
PneumoniaInfections and infestations16/4676/237
Hepatic failureHepatobiliary disorders8/4678/237
Hepatic encephalopathyNervous system disorders15/4671/237
AscitesGastrointestinal disorders12/4673/237
DyspnoeaRespiratory, thoracic and mediastinal disorders10/4672/237
Oesophageal varices haemorrhageGastrointestinal disorders7/4675/237
AstheniaGeneral disorders9/4670/237
Most frequent other events
Showing 10 of 25
Most frequent other events
EventCabozantinib (XL184)Placebo
DiarrhoeaGastrointestinal disorders251/46743/237
Decreased appetiteMetabolism and nutrition disorders224/46743/237
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders217/46712/237
FatigueGeneral disorders209/46770/237
NauseaGastrointestinal disorders147/46741/237
HypertensionVascular disorders137/46713/237
VomitingGastrointestinal disorders118/46724/237
Aspartate aminotransferase increasedInvestigations103/46727/237
AstheniaGeneral disorders99/46717/237
DysphoniaRespiratory, thoracic and mediastinal disorders90/4675/237

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cabozantinib (XL184)PlaceboTotal
Median64.0 (22 to 86)64.0 (24 to 86)64.0 (22 to 86)
Age, Customized
Age, Customized(Participants)Cabozantinib (XL184)PlaceboTotal
Age, Customized — < 65 years old240124364
Age, Customized — 65 to < 75 years old15875233
Age, Customized — 75 to < 85 years old6735102
Age, Customized — ≥ 85 years old538
Sex: Female, Male
Sex: Female, Male(Participants)Cabozantinib (XL184)PlaceboTotal
Female9135126
Male379202581
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cabozantinib (XL184)PlaceboTotal
Hispanic or Latino181230
Not Hispanic or Latino417215632
Unknown or Not Reported351045
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cabozantinib (XL184)PlaceboTotal
American Indian or Alaska Native000
Asian15982241
Native Hawaiian or Other Pacific Islander303
Black or African American81119
White264130394
More than one race011
Unknown or Not Reported361349
Geographic Region
Geographic Region(Participants)Cabozantinib (XL184)PlaceboTotal
Australia / New Zealand151126
Asia11659175
Europe231108339
North America (USA / Canada)10859167
Presence of extrahepatic spread of disease and/or macrovascular invasion (stratification per IxRS)
Presence of extrahepatic spread of disease and/or macrovascular invasion (stratification per IxRS)(Participants)Cabozantinib (XL184)PlaceboTotal
Yes368186554
No10251153
Etiology of disease (stratification factor per IxRS),
Etiology of disease (stratification factor per IxRS),(Participants)Cabozantinib (XL184)PlaceboTotal
HBV (with or without known HCV)18290272
HCV (without known HBV)10051151
Other (neither HBV nor HCV)18896284

6 further baseline measures are reported on the registry.

08

Study locations

104 sites
  • Corona, California 92879, United States
  • Los Angeles, California 90033, United States
  • San Diego, California 92123, United States
  • San Francisco, California 94115, United States
  • Gainesville, Florida 32610, United States
  • Atlanta, Georgia 30318, United States
  • Honolulu, Hawaii 96815, United States
  • Chicago, Illinois 60637, United States
  • Burlington, Massachusetts 01805, United States
  • Rochester, Minnesota 55905, United States
  • Kansas City, Missouri 64128, United States
  • Saint Louis, Missouri 63110, United States
  • Las Vegas, Nevada 89109, United States
  • East Orange, New Jersey 07018, United States
  • New York, New York 10032, United States
  • New York, New York 10065, United States
  • Valhalla, New York 10595, United States
  • Dallas, Texas 75246, United States
  • San Antonio, Texas 78215, United States
  • Seattle, Washington 98104, United States
  • Seattle, Washington 98109, United States
  • Spokane, Washington 99208, United States
  • Camperdown, New South Wales 2050, Australia
  • Concord, New South Wales 2139, Australia
  • Darlinghurst, New South Wales 2010, Australia
  • Kogarah, New South Wales 2217, Australia
  • Westmead, New South Wales 2145, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Melbourne, Victoria 3050, Australia
  • Perth, Western Australia 6000, Australia
  • Edegem, Antwerpen 2650, Belgium
  • La Louvière, Hainaut 7100, Belgium
  • Gent, Oost-Vlaanderen 9000, Belgium
  • Liege, 4000, Belgium
  • Calgary, Alberta T2N 4N2, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Saskatoon, Saskatchewan S7N 4H4, Canada
  • Nice, Alpes-Maritimes 6202, France
  • Amiens, Somme 80054, France
  • Creteil, Val-de-Marne 94010, France
  • Besançon, 25000, France
  • Bordeaux, 33075, France
  • Clermont-Ferrand, 63003, France
  • Lille, 59037, France
  • Lyon, 69317, France
  • Esslingen am Neckar, Baden-Württemberg 73730, Germany
  • Tübingen, Baden-Württemberg 72076, Germany
  • München, Bayern 81675, Germany
  • Frankfurt am Main, Hessen 60590, Germany
  • Magdeburg, Sachsen-Anhalt 39120, Germany
  • Berlin, 13353, Germany
  • Freiburg, Germany
  • Hong Kong, Hong Kong
  • Dublin, 7, Ireland
  • Bologna, Emilia-Romagna 40138, Italy
  • Faenza, Emilia-Romagna 48018, Italy
  • Meldola, Emilia-Romagna 47014, Italy
  • Rimini, Emilia-Romagna 47900, Italy
  • Roma, Lazio 128, Italy
  • Roma, Lazio 168, Italy
  • Genova, Liguria 16132, Italy
  • Milan, Lombardia 20122, Italy
  • Rozzano, Lombardia 20089, Italy
  • Palermo, Sicilia 90127, Italy
  • Padova, Veneto 35128, Italy
  • Goyang, Gyeonggido 410-769, Korea, Republic of
  • Busan, 602-739, Korea, Republic of
  • Seongnam, 463-707, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Seoul, 136-705, Korea, Republic of
  • Seoul, 137-701, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Suwon-si, 443-721, Korea, Republic of
  • Maastricht, Limburg 6229 HX, Netherlands
  • Amsterdam, Noord-Holland 1081 HV, Netherlands
  • Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Leiden, Zuid-Holland 2333 ZA, Netherlands
  • Auckland, North Island 1003, New Zealand
  • Olsztyn, Warminsko-Mazurskie 10-513, Poland
  • Myslowice, 41-400, Poland
  • Poznan, 60-569, Poland
  • Cluj-Napoca, Cluj 400015, Romania
  • Brasov, 500019, Romania
  • Singapore, 119074, Singapore
  • Singapore, 169610, Singapore
  • Singapore, 308433, Singapore
  • Elche, Alicante 3293, Spain
  • Majadahonda, Madrid 28222, Spain
  • Torrejon de Ardoz, Madrid 28850, Spain
  • Madrid, 28007, Spain
  • Madrid, 28041, Spain
  • Zaragoza, 50009, Spain
  • Liuying Township, Tainan 736, Taiwan
  • Taichung, 40705, Taiwan
  • Taipei, 100, Taiwan
  • Edirne, 22030, Turkey
  • Gaziantep, 27100, Turkey
  • Wirral, England CH63 4JY, United Kingdom

Showing the first 100 of 104 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Freemantle N, Mollon P, Meyer T, Cheng AL, El-Khoueiry AB, Kelley RK, Baron AD, Benzaghou F, Mangeshkar M, Abou-Alfa GK. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. Eur J Cancer. 2022 Jun;168:91-98. doi: 10.1016/j.ejca.2022.03.021. Epub 2022 Apr 26. PubMed 35487183 ↗
  • El-Khoueiry AB, Meyer T, Cheng AL, Rimassa L, Sen S, Milwee S, Kelley RK, Abou-Alfa GK. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer. 2022 Apr 9;22(1):377. doi: 10.1186/s12885-022-09453-z. PubMed 35397508 ↗
  • Kelley RK, Miksad R, Cicin I, Chen Y, Klumpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer. 2022 Mar;126(4):569-575. doi: 10.1038/s41416-021-01532-5. Epub 2021 Oct 7. PubMed 34621044 ↗
  • Trojan J, Mollon P, Daniele B, Marteau F, Martin L, Li Y, Xu Q, Piscaglia F, Zaucha R, Sarker D, Lim HY, Venerito M. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein >/= 400 ng/mL: A Matching-Adjusted Indirect Comparison. Adv Ther. 2021 May;38(5):2472-2490. doi: 10.1007/s12325-021-01700-2. Epub 2021 Apr 6. PubMed 33822328 ↗
  • Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020 Aug;5(4):e000714. doi: 10.1136/esmoopen-2020-000714. PubMed 32847838 ↗
  • Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klumpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. PubMed 29972759 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Oct 2017 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2013
First posted
Jul 25, 2013
Start
Sep 26, 2013
Primary completionActual
Oct 16, 2017
CompletionActual
Jan 12, 2021
Results first posted
Mar 1, 2019
Last update
May 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01908426
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jul 25, 2013
Start date
Sep 26, 2013
Primary completion
Oct 16, 2017
Completion
Jan 12, 2021
Results posted
Mar 1, 2019
Last update
May 6, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion